TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22252796
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 220 mg (test treatment)
Study: 22252796
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg administered subcutaneously once daily for 3 days
Study: 22252796
Drug: Enoxaparin pre-treatment
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin pre-treatment
Study: 17621023
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative medication (control group).
Study: 15846258
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with unfractionated heparin (UFH) as adjunctive antithrombin therapy
Study: 11598429
Drug: CBT +
Normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBT + Fluoxetine (FLX)
Study: 9161352
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (150 mg daily for 28 days)
Study: 7966841
Drug: Smoking intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking intervention plus bronchodilator
Study: 7966841
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (bronchodilator)
Study: 28285617
Drug: Bee propolis
Normalized name: Bee propolis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bee propolis (300 mg three times a day for a total of 900 mg/d)
Study: 28285617
Drug: Placebo (similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar pills lacking propolis)
Study: 28285617
Drug: No significant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No significant difference reported for other lipids or insulin resistance indices between the two groups.
Study: 14592846
Drug: 900 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/d vitamin E supplementation
Study: 14592846
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without vitamin E
Study: 7002355
Drug: Aspirin (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (325 mg four times daily)
Study: 7002355
Drug: Sulfinpyrazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfinpyrazone (200 mg four times daily)
Study: 3903504
Drug: Both aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both aspirin and sulfinpyrazone
Study: 20630944
Drug: Telmisartan (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (160 mg/day)
Study: 8251051
Drug: Thiamine 3
Normalized name: thiamine 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine 3 to 8 g/day administered orally
Study: 4022687
Drug: Solution A
Normalized name: I.V. SOLUTION ADDITIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution A (90 mmol/L sodium, 20 g/L glucose, bicarbonate)
Study: 4022687
Drug: Solution B
Normalized name: DONISLECEL-JUJN RINSE SOLUTION BAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution B (50 mmol/L sodium, 20 g/L glucose, citrate)
Study: 4022687
Drug: Solution C
Normalized name: Salt solution combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution C (30 mmol/L sodium, 20 g/L glucose, citrate)
Study: 4022687
Drug: Solution D
Normalized name: KIT, PATCH, MEDICATED AND SOLUTION DROPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution D (30 mmol/L sodium, 50 g/L glucose, citrate)
Study: 30056415
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy program (Control group)
Study: 18389608
Drug: Curation algorithm
Normalized name: oxymetazoline hydrochloride Nasal Spray [Duration]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curation algorithm for chronic gastritis after antihelicobacter therapy
Study: 11530993
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg LJP 394 weekly
Study: 11530993
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg LJP 394 weekly
Study: 9272319
Drug: Desmopressin intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin intranasal spray (20 mg)
Study: 9272319
Drug: Desmopressin intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin intranasal spray (40 mg)
Study: 9272319
Drug: Desmopressin intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin intranasal spray
Study: 3091196
Drug: Lay therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lay therapy treatment
Study: 18257181
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Xianling Gubao Capsules
Study: 12825105
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (Viagra) 25, 50, or 100 mg
Study: 10594466
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (MgS) - 12 mmol magnesium lactate daily for 1 month
Study: 30938842
Drug: Vortioxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (10 mg/day for 1 week, then increasing to 20 mg/day)
Study: 26860490
Drug: Combined epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined epidural analgesia with total intravenous anaesthesia (Group E)
Study: 26860490
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (Group C)
Study: 22825227
Drug: Selling syringes
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selling syringes to injection drug users (IDUs)
Study: 19741485
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at rates of 10 to 160 mg . kg(‐1). h(‐1)
Study: 18085142
Drug: Aricept, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aricept, 2.5 mg (oral administration)
Study: 12364843
Drug: DVP +
Normalized name: Divalproex Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: DVP + quetiapine (450 mg/day)
Study: 9819796
Drug: R24 monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R24 monoclonal antibody (0, 5, 25, 50 mg/m2) with IL-2/α-IFN
Study: 9819796
Drug: R24 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: R24 treatment
Study: 9819796
Drug: No R24
Normalized name: NO
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No R24 treatment (control group)
Study: 337773
Drug: elantrine added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: elantrine added to L-dopa treatment
Study: 337773
Drug: elantrine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: elantrine with L-dopa (or Sinemet)
Study: 1851071
Drug: Insulin withdrawal
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin withdrawal
Study: 30506451
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy after insulin withdrawal
Study: 30506451
Drug: Insulin-controlled euglycaemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-controlled euglycaemia (control)
Study: 28249150
Drug: Nemolizumab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemolizumab 2.0 mg/kg every 8 weeks
Study: 18309155
Drug: Chlorthalidone-based antihypertensive
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone-based antihypertensive regimen
Study: 14532798
Drug: Periprostatic infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periprostatic infiltration with 10 ml 1% lidocaine
Study: 8986487
Drug: Continuous zero‐balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous zero‐balanced hemofiltration (HF) without dialysis (ultrafiltrate rate 2 l/h)
Study: 31425951
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (100 μg or 4000 IU daily for 12 weeks)
Study: 27619558
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with gemigliptin 50 mg qd + metformin 1000 to 2000 mg qd
Study: 27619558
Drug: Gemigliptin monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin monotherapy 50 mg qd
Study: 27619558
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy 1000 to 2000 mg qd
Study: 27343309
Drug: Antagonist protocol
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist protocol
Study: 24746976
Drug: ONS-EPA (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONS-EPA (oral nutritional supplement containing eicosapentaenoic acid)
Study: 11800062
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg combined with hydrochlorothiazide (HCTZ) 12.5 mg
Study: 10082603
Drug: Tissue engineering
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tissue engineering materials (e.g., Apligraf, Integra)
Study: 10082603
Drug: Polymeric wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymeric wound dressings (e.g., Tegaderm, Opsite)
Study: 10082603
Drug: Dermal replacements
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal replacements (e.g., reconstituted collagen and chondroitan sulfate)
Study: 8151608
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg twice daily after six weeks
Study: 8151608
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg twice daily after ten days
Study: 3340420
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine injection for myofascial trigger points
Study: 3340420
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone (10 mg)
Study: 27247177
Drug: Paliperidone Palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone Palmitate (PP) 39-234 mg
Study: 27247177
Drug: Haloperidol Decanoate
Normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol Decanoate (HD) 25-200 mg
Study: 25896862
Drug: MRI-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided treatment strategy
Study: 25896862
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment strategy
Study: 21041965
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (25 females, no treatment)
Study: 15536230
Drug: Topiramate (96
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (96 mg/d)
Study: 15536230
Drug: Topiramate (192
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (192 mg/d)
Study: 11437473
Drug: NN703 (tabimorelin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN703 (tabimorelin) 1.71 mg/kg
Study: 11032702
Drug: NN703 (tabimorelin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN703 (tabimorelin) 3.0 mg/kg
Study: 11437473
Drug: NN703 (tabimorelin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN703 (tabimorelin) 4.5 mg/kg
Study: 11437473
Drug: NN703 (tabimorelin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NN703 (tabimorelin) 6.86 mg/kg
Study: 9541440
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with intraoperative 0.2mg/ml MMC
Study: 9541440
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with intraoperative 0.4mg/ml MMC
Study: 1464895
Drug: Trandolapril 4
Normalized name: trandolapril 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 4 mg
Study: 7527100
Drug: Trandolapril (0.5-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (0.5-4 mg range)
Study: 29477665
Drug: vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vemurafenib 960 mg tablets twice daily for 52 weeks
Study: 25795646
Drug: Fingolimod 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fingolimod 1.25 mg/day
Study: 25795646
Drug: Placebo to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Fingolimod 0.5 mg/day
Study: 25795646
Drug: Placebo to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Fingolimod 1.25 mg/day
Study: 23764639
Drug: Full PopART
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full PopART intervention strategy including home-based HIV testing, linkage to care, universal antiretroviral therapy, voluntary medical male circumcision, diagnosis and treatment of STIs, behavioral counseling, and condom distribution.
Study: 21940595
Drug: FR-MDM (fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: FR-MDM (fortified rice midday meal with 19 mg Fe)
Study: 11160635
Drug: Caffeine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (400 mg/70 kg)
Study: 11160635
Drug: Nicotine (0.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (0.75, 1.5, and 3.0 mg/70 kg)
Study: 11160635
Drug: Caffeine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (150 mg/70 kg)
Study: 8069732
Drug: Subcutaneous erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous erythropoietin (150 U/Kg/wk to 180 U/Kg/wk)
Study: 8069732
Drug: Intravenous erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous erythropoietin (75 U/Kg/wk to 90 U/Kg/wk)
Study: 8069732
Drug: Subcutaneous erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous erythropoietin (for CAPD patients)
Study: 8069732
Drug: Subcutaneous and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous and intravenous erythropoietin (various doses)
Study: 8069732
Drug: Subcutaneous erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous erythropoietin
Study: 3056073
Drug: 4-Methylpyrazole 10
Normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-Methylpyrazole 10 mg/kg
Study: 3056073
Drug: 4-Methylpyrazole 20
Normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-Methylpyrazole 20 mg/kg
Study: 3056073
Drug: 4-Methylpyrazole 50
Normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-Methylpyrazole 50 mg/kg
Study: 3056073
Drug: 4-Methylpyrazole 100
Normalized name: 4-methylpyrazol
DrugBank: Fomepizole (DB01213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-Methylpyrazole 100 mg/kg
Study: 27287389
Drug: 21mg/day nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21mg/day nicotine patch and four brief behavior counseling sessions over 8 weeks
Study: 15143375
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch therapy
Study: 23612399
Drug: Neuromidin (ipidacrinum)
Normalized name: Neurokinin p
DrugBank: Substance P (DB19198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromidin (ipidacrinum) therapy for 2 months
Study: 16450017
Drug: Combined folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined folic acid 2.5 mg, vitamin B6 50 mg, and vitamin B12 1 mg daily
Study: 8466836
Drug: Non-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment control group (N = 29)
Study: 29035602
Drug: Dextrose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose (1 g/kg body mass)
Study: 29035602
Drug: Modified Amylomaize-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Amylomaize-7 (1 g/kg body mass)
Study: 28003294
Drug: Non-operative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative management (NOM) with antibiotic therapy alone
Study: 28003294
Drug: Operative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative management with prophylactic antibiotics and appendicectomy
Study: 29901635
Drug: Rapamycin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapamycin treatment
Study: 22578337
Drug: Becaplermin gel
Normalized name: becaplermin Topical Gel
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Becaplermin gel (Regranex(®))
Study: 15966757
Drug: Modafinil 800
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 800 mg/day
Study: 2556433
Drug: Serotype 1
Normalized name: Aspergillus fumigatus serotype 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype 1 reassortant vaccine
Study: 2556433
Drug: Serotype 2
Normalized name: Pneumococcal polysaccharide serotype 23F
DrugBank: Streptococcus pneumoniae type 23f capsular polysaccharide antigen (DB10340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype 2 reassortant vaccine
Study: 2556433
Drug: Serotype 3
Normalized name: HUMAN ADENOVIRUS B SEROTYPE 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotype 3 (rhesus rotavirus) vaccine
Study: 2556433
Drug: Bivalent preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent preparation (serotypes 1 and 3) vaccine
Study: 28543302
Drug: TOBY therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOBY therapy plus treatment-as-usual (n=41)
Study: 28543302
Drug: treatment-as-usual (n=39)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment-as-usual (n=39)
Study: 21236483
Drug: Aliskiren plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren plus amlodipine (150 mg aliskiren plus 5 mg amlodipine)
Study: 21236483
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (300 mg aliskiren plus 10 mg amlodipine)
Study: 19120336
Drug: Formulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation with 0.5% benzyl nicotinate (BN) and 10% fat
Study: 19120336
Drug: Formulation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation with 0.3% betamethasone valerate (BV) and low fat content
Study: 19120336
Drug: Formulations with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations with higher fat content (not specified)
Study: 17538086
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (15 mg temsirolimus weekly + 6 million U interferon alfa three times weekly)
Study: 17538086
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (3 million U subcutaneously three times weekly, increasing to 18 million U)
Study: 14742392
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous ephedrine
Study: 10360849
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg/15 min followed by 0.4 mg/h) + Ketamine (0.3 mg x kg(‐1) x 15 min(‐1) followed by 0.3 mg x kg(‐1) x h(‐1))
Study: 10360849
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Ketamine (0.3 mg x kg(‐1) x 15 min(‐1) followed by 0.3 mg x kg(‐1) x h(‐1))
Study: 6125164
Drug: metoprolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (1 mg i.v.)
Study: 6125164
Drug: oxprenolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxprenolol (1 mg i.v.)
Study: 6125164
Drug: propranolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (1 mg i.v.)
Study: 29383569
Drug: Levetiracetam extended-release
Normalized name: Levetiracetam Extended-Release Tablets
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam extended-release (ER) tablets
Study: 29383569
Drug: Levetiracetam ER
Normalized name: LevETIRAcetam ER
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam ER tablets with food
Study: 29383569
Drug: Levetiracetam immediate-release
Normalized name: levetiracetam Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam immediate-release (IR) tablets
Study: 20181806
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Atorvastatin + Fish oils)
Study: 10077348
Drug: Triiodothyronine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triiodothyronine administration
Study: 10077348
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GH and triiodothyronine
Study: 7554199
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment group
Study: 31519475
Drug: Clobazam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam (40 mg)
Study: 21224820
Drug: Heparin-coated ECC-set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated ECC-set (group B)